Company Overview and News

 
ISM Communications sells 30% of shares to Singapore fund

2018-08-28 bworldonline
ISM Communications, Inc. is selling around 30% of its shares to a Singapore-based fund management firm for P1.22 billion, a few weeks after it sold a controlling stake in the company to businessman Dennis A. Uy.
ISM

 
ISM sells 30% of shares for P1.22 billion

2018-08-28 bworldonline
ISM Communications, Inc. is selling around 30% of its shares to a Singapore-based fund management firm for P1.22 billion, a few weeks after it sold a majority stake in the company to businessman Dennis A. Uy.
ISM

 
Dennis Uy acquires 45.13% of ISM

2018-08-16 business.inquirer.net
Davao-based Dennis Uy has gained control of 45.13 percent of holding firm ISM Communications Corp. by finalizing a deal to buy new common shares worth P1.28 billion.
PSKXF PHSXY PSE ISM

 
Dennis Uy buys stake in ISM for P1.28B

2018-08-16 bworldonline
DAVAO-BASED businessman Dennis A. Uy continues his acquisition spree with the purchase of P1.28 billion worth of shares in listed firm ISM Communications Corp.
H2O ISM

 
Dennis Uy buys 45% of ISM Communications

2018-08-16 bworldonline
Davao-based businessman Dennis A. Uy continues his acquisition spree with the purchase of P1.28 billion worth of shares in listed firm ISM Communications Corp.
ISM

 
Dennis Uy to buy stake in ISM via share issue

2018-06-22 bworldonline
ISM Communications Corp. said its board has authorized the executive committee to issue shares, adding that Udenna Group’s Dennis A. Uy has “committed” to participate in the fund-raising exercise.
ISM

 
ISM board approves fundraising through share issuance

2018-06-22 bworldonline
The board of directors of ISM Communications Corp. has authorized its executive committee to raise funds through the issuance of treasury shares as well as unissued shares from of its authorized capital stock, the company told the stock exchange on Friday.
ISM

 
ISM board approves sale of treasury shares to unit

2018-05-02 bworldonline
ISM Communications Corp. is selling treasury shares to give the holding firm some flexibility to finance possible investments and issue cash dividends.
ISM

 
ISM Communications to sell treasury shares worth P560 million

2018-05-02 bworldonline
In a disclosure to the stock exchange on Wednesday, May 2, ISM said its board of directors approved the sale of 560 million treasury shares to wholly-owned subsidiary ISM Equities Corp. at a price of P1.00 per share.
ISM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...